Terms: = Prostate cancer AND FOXO1, Q12778, FOXO1A, 2308, ENSG00000150907, FKH1, FKHR
86 results:
1. miR-92a-1-5p enriched prostate cancer extracellular vesicles regulate osteoclast function via MAPK1 and foxo1.
Yu L; Sui B; Zhang X; Liu J; Hao X; Zheng L
J Exp Clin Cancer Res; 2023 May; 42(1):109. PubMed ID: 37131239
[TBL] [Abstract] [Full Text] [Related]
2. Anticancer Activity of Methyl Protodioscin against prostate cancer by Modulation of Cholesterol-Associated MAPK Signaling Pathway via foxo1 Induction.
Chen J; Qin P; Tao Z; Ding W; Yao Y; Xu W; Yin D; Tan S
Biol Pharm Bull; 2023; 46(4):574-585. PubMed ID: 37005301
[TBL] [Abstract] [Full Text] [Related]
3. SGK2 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating GPX4.
Cheng L; He Q; Liu B; Chen L; Lv F; Li X; Li Y; Liu C; Song Y; Xing Y
Cell Death Dis; 2023 Jan; 14(1):74. PubMed ID: 36720852
[TBL] [Abstract] [Full Text] [Related]
4. miR-29b Regulates Lung cancer Progression by Downregulating FEM1B and Inhibiting the FOX01/AKT Pathway.
Zhang H; Wang R; Deng Q
Comput Math Methods Med; 2022; 2022():3110330. PubMed ID: 36003920
[TBL] [Abstract] [Full Text] [Related]
5. Clinical Evaluation of foxo1 as a Tumor Suppressor in prostate cancer.
Yang N; Wu J; Zhang T; Yang F; Shao J; He C; Qin L
Comput Math Methods Med; 2021; 2021():8773423. PubMed ID: 34552661
[TBL] [Abstract] [Full Text] [Related]
6. foxo1 inhibits prostate cancer cell proliferation via suppressing E2F1 activated NPRL2 expression.
Tang Y; Jiang L; Zhao X; Hu D; Zhao G; Luo S; Du X; Tang W
Cell Biol Int; 2021 Dec; 45(12):2510-2520. PubMed ID: 34459063
[TBL] [Abstract] [Full Text] [Related]
7. Baicalein ameliorates osteoporosis via AKT/foxo1 signaling.
Cai P; Lu Y; Yin Z; Wang X; Zhou X; Li Z
Aging (Albany NY); 2021 Jul; 13(13):17370-17379. PubMed ID: 34198266
[TBL] [Abstract] [Full Text] [Related]
8. A research of STEAP1 regulated gastric cancer cell proliferation, migration and invasion in vitro and in vivos.
Zhang Z; Hou WB; Zhang C; Tan YE; Zhang DD; An W; Pan SW; Wu WD; Chen QC; Xu HM
J Cell Mol Med; 2020 Dec; 24(24):14217-14230. PubMed ID: 33128353
[TBL] [Abstract] [Full Text] [Related]
9. Targeting the PLK1-foxo1 pathway as a novel therapeutic approach for treating advanced prostate cancer.
Gheghiani L; Shang S; Fu Z
Sci Rep; 2020 Jul; 10(1):12327. PubMed ID: 32704044
[TBL] [Abstract] [Full Text] [Related]
10. The ERG-Regulated
Angeles AK; Heckmann D; Flosdorf N; Duensing S; Sültmann H
Mol Cancer Res; 2020 Oct; 18(10):1545-1559. PubMed ID: 32646965
[TBL] [Abstract] [Full Text] [Related]
11. Development of an autophagy-related gene expression signature for prognosis prediction in prostate cancer patients.
Hu D; Jiang L; Luo S; Zhao X; Hu H; Zhao G; Tang W
J Transl Med; 2020 Apr; 18(1):160. PubMed ID: 32264916
[TBL] [Abstract] [Full Text] [Related]
12. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in prostate cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract] [Full Text] [Related]
13. Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade prostate cancer Senescence.
Nagesh PKB; Chowdhury P; Hatami E; Kumari S; Kashyap VK; Tripathi MK; Wagh S; Meibohm B; Chauhan SC; Jaggi M; Yallapu MM
ACS Appl Mater Interfaces; 2019 Oct; 11(42):38537-38554. PubMed ID: 31553876
[TBL] [Abstract] [Full Text] [Related]
14. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
15. Nodal pathway activation due to Akt1 suppression is a molecular switch for prostate cancer cell epithelial-to-mesenchymal transition and metastasis.
Alwhaibi A; Verma A; Artham S; Adil MS; Somanath PR
Biochem Pharmacol; 2019 Oct; 168():1-13. PubMed ID: 31202735
[TBL] [Abstract] [Full Text] [Related]
16. LITAF Enhances Radiosensitivity of Human Glioma Cells via the foxo1 Pathway.
Huang C; Chen D; Zhu H; Lv S; Li Q; Li G
Cell Mol Neurobiol; 2019 Aug; 39(6):871-882. PubMed ID: 31098771
[TBL] [Abstract] [Full Text] [Related]
17. CTCF regulates the FoxO signaling pathway to affect the progression of prostate cancer.
Shan Z; Li Y; Yu S; Wu J; Zhang C; Ma Y; Zhuang G; Wang J; Gao Z; Liu D
J Cell Mol Med; 2019 May; 23(5):3130-3139. PubMed ID: 30873749
[TBL] [Abstract] [Full Text] [Related]
18. Early detection of the PAX3-foxo1 fusion gene in circulating tumor-derived DNA in a case of alveolar rhabdomyosarcoma.
Eguchi-Ishimae M; Tezuka M; Kokeguchi T; Nagai K; Moritani K; Yonezawa S; Tauchi H; Tokuda K; Ishida Y; Ishii E; Eguchi M
Genes Chromosomes Cancer; 2019 Aug; 58(8):521-529. PubMed ID: 30739374
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of foxo1 expression.
Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
[TBL] [Abstract] [Full Text] [Related]
20. Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Shih JC
J Neural Transm (Vienna); 2018 Nov; 125(11):1553-1566. PubMed ID: 30259128
[TBL] [Abstract] [Full Text] [Related]
[Next]
